



Company Announcement

Nykode Therapeutics to Present at Jefferies Healthcare Conference

Oslo, Norway, November 7, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig, will present and host 1x1 meetings at the 2023 Jefferies Healthcare Conference in London on Thursday, November 16, 2023, at 8:00 a.m. GMT / 9:00 a.m. CET.

The presentation slides will be available in the Investors section of the Company's website at <https://nykode.com/investors/financial-reports-and-presentations/>.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells (APC), which have been shown to induce broad, strong, and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech, within oncology, and a multi-target collaboration with Regeneron, within oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

Contact for Nykode Therapeutics ASA:

Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com



Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway